Imunon (IMNN) Registration filing summary

Company overview and business model

• Clinical-stage biotech developing nonviral DNA platforms; lead TheraPlas modality encodes proteins and cytokines for solid-tumor treatment.

• Lead candidate IMNN-001 is a localized DNA immunotherapy for advanced ovarian cancer; OVATION 3 Phase 3 compares IMNN-001 plus chemotherapy with chemotherapy alone, with enrollment targeted for completion in Q1 2029.

• July 2026 preliminary MRD Study findings: MRD positivity 44% vs 67%, ctDNA clearance 87.5% vs 62.5%, and no evidence of disease 100% vs 56%; August IDMC recommended continuation without modification.

• September 2026 NCI/CTEP CRADA supports additional IMNN-001 development in other solid-tumor indications and combinations.

• October 20, 2026 asset purchase agreement would transfer ThermoDox assets to VoxelDox Therapeutics, subject to a $2.5M funding condition; consideration includes 4.76% equity, milestones and royalties.

Financial performance and metrics

• Q2 and H1 2026 net losses were $2.8M and $7.1M; cumulative net losses reached $428.4M, with $6.9M cash and cash equivalents at June 30, 2026.

• FY2025 audited statements included a going-concern explanatory paragraph; without additional funding, year-end 2025 cash was insufficient for at least one year of operations from issuance.

• June 30, 2026 net tangible book value was $4.2M, or $0.90/share; assuming the maximum offering, adjusted value was $27.2M, or $1.03/share, with $0.22/share dilution to new investors.

• Assuming maximum sale at $1.25/share and no prefunded warrants or warrant exercises, adjusted cash is $29.9M and total capitalization $27.2M.

Use of proceeds and capital allocation

• Estimated net proceeds are $23M at maximum offering size; estimates at 75%, 50% and 25% of securities sold are $17.2M, $11.4M and $5.6M, respectively.

• Proceeds are intended for general corporate purposes, primarily IMNN-001 clinical development, capital expenditures and working capital; some may repay Streeterville Capital debt.

• Management retains broad discretion over proceeds; no minimum raise or escrow applies, so funds may be used even if sales are insufficient to meet planned objectives.

• Cash exercise of all investor and placement-agent warrants at the assumed $1.25 exercise price could generate an additional $156.9M; cashless exercises or non-exercise could limit proceeds.